Women need to be warned about dangers of hormone replacement therapy
BMJ 1997; 314 doi: https://doi.org/10.1136/bmj.314.7077.376b (Published 01 February 1997) Cite this as: BMJ 1997;314:376
- Elizabeth H Price, Consultant medical microbiologista,
- Helen K Little, Consultant radiologistb,
- Ellen C G Grant, Honorary secretary, DASHc,
- C Michael Steel, Professor of medical sciencesd
- a Great Ormond St Hospital for Children NHS Trust, London WC1N 3JH
- b Bronglais Hospital, Aberystwyth, Dyfed SY23 1ER
- c 20 Coombe Ridings, Kingston upon Thames KT2 7JU
- d School of Biological and Medical Sciences, St Andrews University, St Andrews KY16 9TS1
Editor–We welcome the responses generated by our letter emphasising the various risks of hormone replacement therapy.1 The possibility of an aggregate net loss of life was discussed by Klim McPherson in his editorial.2 This concern is strengthened by doubts about cardioprotection and the clear evidence, recently uncovered, that hormone replacement therapy increases primary venous thromboembolic disease.3
Findings of an increased risk of breast cancer in large, well conducted studies are not cancelled out by the existence of apparently negative studies. In fact, all of …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.